Carnegie Investment Counsel Has $5.52 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Carnegie Investment Counsel raised its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 51.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 102,112 shares of the company’s stock after purchasing an additional 34,500 shares during the quarter. Carnegie Investment Counsel’s holdings in CRISPR Therapeutics were worth $5,515,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of CRISPR Therapeutics by 107.4% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 35,001 shares of the company’s stock worth $1,890,000 after acquiring an additional 18,125 shares during the last quarter. Hedges Asset Management LLC lifted its stake in CRISPR Therapeutics by 12.5% in the 2nd quarter. Hedges Asset Management LLC now owns 21,800 shares of the company’s stock valued at $1,177,000 after purchasing an additional 2,425 shares during the last quarter. Raymond James & Associates boosted its position in CRISPR Therapeutics by 10.0% in the second quarter. Raymond James & Associates now owns 38,433 shares of the company’s stock valued at $2,076,000 after buying an additional 3,479 shares in the last quarter. Blue Trust Inc. boosted its position in CRISPR Therapeutics by 2,932.7% in the second quarter. Blue Trust Inc. now owns 1,486 shares of the company’s stock valued at $80,000 after buying an additional 1,437 shares in the last quarter. Finally, SteelPeak Wealth LLC grew its stake in shares of CRISPR Therapeutics by 52.7% during the second quarter. SteelPeak Wealth LLC now owns 15,660 shares of the company’s stock worth $846,000 after buying an additional 5,407 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock traded down $0.51 on Tuesday, hitting $49.32. The company had a trading volume of 745,247 shares, compared to its average volume of 1,575,489. CRISPR Therapeutics AG has a 1 year low of $37.55 and a 1 year high of $91.10. The stock has a 50 day moving average of $55.29 and a 200-day moving average of $62.07. The stock has a market capitalization of $4.19 billion, a price-to-earnings ratio of -18.01 and a beta of 1.70.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to analyst estimates of $12.31 million. The company’s quarterly revenue was down 99.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.98) EPS. Equities analysts anticipate that CRISPR Therapeutics AG will post -5.52 earnings per share for the current year.

Analyst Ratings Changes

CRSP has been the subject of a number of research reports. Truist Financial dropped their price target on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, August 12th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research report on Friday. Stifel Nicolaus reduced their price target on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Royal Bank of Canada dropped their price objective on shares of CRISPR Therapeutics from $66.00 to $60.00 and set a “sector perform” rating for the company in a report on Tuesday, August 6th. Finally, Guggenheim reissued a “neutral” rating on shares of CRISPR Therapeutics in a report on Friday, June 28th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $75.63.

Insider Buying and Selling

In related news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction on Friday, June 21st. The stock was sold at an average price of $56.09, for a total transaction of $188,798.94. Following the sale, the chief operating officer now directly owns 6,745 shares in the company, valued at $378,327.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.